Sublingual Edaravone Dexborneol Tablet Shows Superior Cost-Effectiveness for Acute Ischemic Stroke Treatment
核心洞察
A new cost-effectiveness analysis demonstrates that edaravone dexborneol sublingual tablet (EDSL) offers superior economic value compared to the injectable formulation for acute ischemic stroke patients.
The study found no statistically significant difference in clinical efficacy between the two formulations, with comparable rates of favorable functional outcomes.
EDSL achieved an incremental cost-effectiveness ratio of -¥3935.13 per quality-adjusted life year gained, indicating cost savings with similar therapeutic benefits.
A comprehensive cost-effectiveness analysis from China Pharmaceutical University reveals that edaravone dexborneol sublingual tablet (EDSL) represents a more economically favorable treatment option for acute ischemic stroke (AIS) patients compared to the traditional injectable formulation. The study, conducted from the Chinese healthcare system perspective, demonstrates significant cost advantages while maintaining comparable clinical efficacy.
Clinical Efficacy Comparison
The analysis utilized clinical data from the TASTE-SL and TASTE trials, employing stabilized inverse probability of treatment weighting (sIPTW) to adjust for baseline characteristics between treatment groups. Results showed no statistically significant difference in the proportion of patients achieving modified Rankin Scale (mRS) scores ≤1 between EDSL and edaravone dexborneol concentrated solution for injection (EDCSI) groups.
Using Average Treatment Effect (ATE) weighting, 69.3% of EDSL patients achieved favorable outcomes compared to 64.6% in the EDCSI group. The Average Treatment Effect on the Treated (ATT) analysis showed similar results, with 71.8% versus 67.6% respectively achieving mRS scores ≤1.
Economic Analysis Results
The economic evaluation employed a combination of short-term decision tree and long-term Markov model approaches. EDSL demonstrated clear cost-effectiveness advantages with an incremental cost-effectiveness ratio (ICER) of -¥3935.13 per quality-adjusted life year (QALY) gained. This negative ICER indicates that EDSL provides cost savings while delivering similar or superior health outcomes.
Model parameters were extracted from published literature, public databases, and expert interviews to ensure comprehensive economic assessment. The analysis incorporated both direct medical costs and long-term healthcare utilization patterns associated with stroke management.
Treatment Accessibility and Administration
The sublingual formulation offers significant practical advantages over the injectable form. EDSL's convenient dosage form provides an alternative administration option that enhances treatment accessibility, particularly important in acute stroke care where rapid intervention is critical. This ease of administration could potentially improve treatment compliance and reduce healthcare resource utilization.
Robustness of Findings
Extensive sensitivity and scenario analyses confirmed the robustness of the base-case results across various parameter assumptions. All analytical approaches consistently supported EDSL's superior cost-effectiveness profile, strengthening confidence in the economic conclusions.
The researchers noted that a full 14-day treatment course may help maximize patient benefits, suggesting optimal treatment duration considerations for clinical practice implementation.
Clinical Implications
The findings support EDSL as a cost-effective therapeutic option for AIS patients, offering comparable efficacy at lower drug costs. This economic advantage, combined with the practical benefits of sublingual administration, positions EDSL as an attractive treatment alternative in acute stroke management protocols.
The study's methodology, incorporating advanced statistical techniques like sIPTW to ensure fair comparison between treatment groups, provides robust evidence for healthcare decision-makers evaluating treatment options for acute ischemic stroke patients.